Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation in Patients With Heart Failure With Reduced Ejection Fraction

NCT05420012 is registered in ClinicalTrials.gov with Josef Stehlik as lead sponsor.

NCT NCT05420012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation in Patients With Heart Failure With Reduced Ejection Fraction
Lead sponsor
Josef Stehlik
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2023
Completion date
October 24, 2024
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, heart failure with reduced ejection fraction (hfref)